- Received tentative FDA approval of YUTREPIA™ (treprostinil) inhalation powder - Expanded use of Treprostinil Injection to include subcutaneous administration - Preparing to launch YUTREPIA in late-2022 pending final FDA approval - Company to host webcast and conference call today at 8:30 a.m.

MORRISVILLE, N.C. , March 10, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that it will report its full year 2021 financial results on Thursday, March 17, 2022 . The company will host a conference call and webcast at 8:30 a.m.

MORRISVILLE, N.C. , Feb. 23, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced the grant of an inducement stock option exercisable for an aggregate of 25,700 shares of Liquidia’s common stock to a newly hired non-executive employee under the Liquidia Corporation 2022

MORRISVILLE, N.C. , Jan. 07, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today the closing of a debt facility on January 7, 2022 , with Silicon Valley Bank (SVB) which provides Liquidia with up to $40.0 million in term loans of which the first $20.0 million was funded at

MORRISVILLE, N.C. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced Dr. Roger Jeffs has been appointed as Chief Executive Officer (CEO) effective January 3, 2022 and will continue as a director on the board. He succeeds Damian deGoa who will remain a director

MORRISVILLE, N.C. , Dec. 29, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that United Therapeutics Corporation (UTC) has filed a stipulation of partial judgment with respect to U.S. Patent No. 9,604,901 (‘901 patent) in the on-going litigation under the Hatch-Waxman

MORRISVILLE, N.C. , Nov. 11, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta , Chief Financial Officer of Liquidia , will provide an update on the company's business during a fireside chat at the Jefferies 2021 Virtual London Healthcare

First dry-powder formulation of treprostinil to meet criteria required for FDA approval Final FDA approval may occur in October 2022 or earlier upon resolution of on-going litigation Conference call and webcast scheduled for today at 9:00 a.m. Eastern Standard Time MORRISVILLE, N.C. , Nov.

-   Increased adoption of generic Treprostinil Injection by patients, physicians and payers -   Completed on-site pre-approval inspections by FDA of two U.S. manufacturing facilities -   Anticipate FDA action on LIQ861 near PDUFA goal date of November 7, 2021 MORRISVILLE, N.C. , Nov.

MORRISVILLE, N.C. , Oct. 08, 2021 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that the U.S. Patent Trial and Appeal Board (PTAB) ruled in its favor in the Inter Partes Review (IPR) proceeding against U.S. Patent No. 9,604,901 (‘901 patent) owned by United Therapeutics